A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma
机构：[1]Phase I Clinical Trial Ward of Medical Oncology Center, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China四川省肿瘤医院[2]Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China[3]Department of Oncology, Mianyang Central Hospital, Mianyang, China[4]Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China[5]Phase I Clinical Trial Ward, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[6]Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China
第一作者机构：[1]Phase I Clinical Trial Ward of Medical Oncology Center, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China
推荐引用方式(GB/T 7714)：
Tongyu Lin,Bin Liu,Xingxiang Pu,et al.A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(16):
APA：
Tongyu Lin,Bin Liu,Xingxiang Pu,Lin Wu,Xiaobo Du...&Xiaoyan Kang.(2024).A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma.JOURNAL OF CLINICAL ONCOLOGY,42,(16)
MLA：
Tongyu Lin,et al."A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma".JOURNAL OF CLINICAL ONCOLOGY 42..16(2024)
医学